Cite
Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
MLA
Konsek-Komorowska, Sonia J., et al. “Chromogranin A (CgA) as a Biomarker in Carcinoid Heart Disease and NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs) Related Carcinoid Syndrome.” Medicina Clinica, vol. 159, no. 2, July 2022, pp. 85–89. EBSCOhost, https://doi.org/10.1016/j.medcli.2021.06.029.
APA
Konsek-Komorowska, S. J., Pęczkowska, M., Kolasińska-Ćwikła, A. D., Konka, M., Chrapowicki, E., & Ćwikła, J. B. (2022). Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome. Medicina Clinica, 159(2), 85–89. https://doi.org/10.1016/j.medcli.2021.06.029
Chicago
Konsek-Komorowska, Sonia J, Mariola Pęczkowska, Agnieszka D Kolasińska-Ćwikła, Marek Konka, Eryk Chrapowicki, and Jarosław B Ćwikła. 2022. “Chromogranin A (CgA) as a Biomarker in Carcinoid Heart Disease and NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs) Related Carcinoid Syndrome.” Medicina Clinica 159 (2): 85–89. doi:10.1016/j.medcli.2021.06.029.